CAMI-NSTEMI评分优化NSTEMI患者院内死亡风险预测的临床研究

心血管病防治知识 ›› 2022, Vol. 12 ›› Issue (20): 19-22.

CAMI-NSTEMI评分优化NSTEMI患者院内死亡风险预测的临床研究

何萍, 李曦铭, 周伽, 刘畅, 李春洁^*

天津市胸科医院,天津 300222

出版日期:2022-07-15 发布日期:2022-09-30
通讯作者: *李春洁
基金资助:
国家重点研发计划项目（2016YFC1301100）; 天津市中医药重点领域科研项目（2022001）; 天津市医学重点学科（专科）建设项目

Online:2022-07-15 Published:2022-09-30

摘要/Abstract

摘要： 目的在非ST段抬高型心肌梗死（NSTEMI）的中国人群中对中国急性心肌梗死注册研究的NSTEMI（CAMI-NSTEMI）评分进行验证并与全球急性冠状动脉事件（GRACE）评分进行比较,探索其对NSTEMI诊疗策略的影响。方法入选NSTEMI患者466例,收集基线资料和院内死亡等数据,计算其CAMI-NSTEMI评分和GRACE评分,利用受试者工作曲线下面积（AUC）和重分类表等统计方法对评分进行验证和比较。结果 CAMI-NSTEMI评分（AUC=0.782,95%置信区间：0.731-0.827））与GRACE评分（AUC=0.743,95%置信区间：0.683-0.802）相比表现出更优秀的分辨能力,并且更准确有效地识别高危患者。结论 CAMI-NSTEMI评分能够更有效预测NSTEMI患者的院内死亡风险,并在此基础上优化NSTEMI患者诊疗策略的选择。

关键词: 非ST段抬高型心肌梗死, 院内死亡, CAMI-NSTEMI评分, GRACE评分, 诊疗策略

何萍, 李曦铭, 周伽, 刘畅, 李春洁. CAMI-NSTEMI评分优化NSTEMI患者院内死亡风险预测的临床研究[J]. 心血管病防治知识, 2022, 12(20): 19-22.

参考文献

[1] Keykhaei M, Ashraf H, Rashedi S, et al.Differences in the 2020 ESC Versus 2015 ESC and 2014 ACC/AHA Guidelines on the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation.[J]. CurrAtheroscler Rep,2021,23(12):77.
[2] Collet Jp, Thiele H, Barbato E, et al.2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2021,42(14):1289-1367.
[3] Song C, Fu R, Li S, et al.Simple risk score based on the China Acute Myocardial Infarction registry for predicting in-hospital mortality among patients with non-ST-segment elevation myocardial infarction: results of a prospective observational cohort study[J]. BMJ Open, 2019, 9(9): e30772.
[4] Fu R, Song C, Yang J, et al.CAMI-NSTEMI Score- China Acute Myocardial Infarction Registry-Derived Novel Tool to Predict In-Hospital Death in Non-ST Segment Elevation Myocardial Infarction Patients[J]. Circ J, 2018, 82(7): 1884-1891.
[5] Carter Jv, Pan J,Raisn,et al.ROC-ing along: Evaluation and interpretation of receiver operating characteeristic curves,2016,159(6):1638-1645.
[6] Mark Dg, Huang J, Kennedy Cj, et al. 60-day major adverse cardiac events in emergency department patients with non-low modified HEART scores[J]. Am J Emerg Med,2020,38(12):2760.e5-2760.
[7] Barthelemy O, Jobs A, Meliga E, et al.Questions and answers on workup diagnosis and risk stratification: a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2021,42(14):1379-1386.
[8] Barbarawi M, Kheuri B, Zayed Y,et al.Meta-analysis of optimal timing of coronary intervention in non-ST-elevation acute coronary syndrome[J]. Catheter Cardiovasc Interv,2020,95(2):185-193.
[9] Wallentin L, Lindhagen L, Arnstrom E, et al.Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study[J]. Lancet, 2016, 388(10054): 1903-1911.
[10] Abtan J, Wiviott Sd, Sorbets E, et al.Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial[J]. Arch Cardiovasc Dis,2021 ,114(3):187-196.
[11] Schloss Mj, Swirski Fk, Nahrendorf M. Modifiable Cardiovascular Risk, Hematopoiesis, and Innate Immunity[J]. Circ Res,2020,126(9):1242-1259.
[12] Yan Xn, Jin Jl, Zhang M, et al.Differential leukocyte counts and cardiovascular mortality in very old patients with acute myocardial infarction: a Chinese cohort study[J]. BMC Cardiovasc Disord,2020,20(1):465.
[13] Powell Wiley Tm, Poirier P, Burke Le, et al.Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association[J]. Circulation,2021,143(21):e984-e1010.